REMARKS

Claims 1-11, 13-20, and 22-29 are pending in the application. Claims 12 and 20 have been cancelled. Claims 1, 4, 9, 13, and 14 have been amended.

Status of the claims

Claims 1, 4, 9, 13, and 14 have been amended to recite a PKR, "wherein PKR comprises the protein kinase catalytic domain of PKR." This amendment adds no new matter. Support for this amendment can be found in the specification, e.g., on page 14, lines 30-35, on page 18, lines 4-7, and on page 19, lines 1-9.

Rejection under 35 U.S.C. § 112, second paragraph

Claims 1-11, 13-20, and 22-29 were rejected as allegedly indefinite for reciting "RNA-activated protein (PKR)," since this term is interpreted by the Examiner to encompass even single amino acids. Applicants respectfully traverse. However, to expedite prosecution, Applicants have amended claims 1, 4, 9, 13, and 14 to recite that the PKR comprises a protein kinase catalytic domain of PKR. Applicants therefore respectfully request that the rejection be withdrawn.

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

USSN 09/972,756

Katze et al.

Page 9

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,

Reg. No. 42,058

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834 Tel: 415-576-0200/Fax: 415-576-0300

60283574 v1